Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925947 · ClinicalTrials.gov registry record · Phase 2
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04925947 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants.
The verdict
NCT04925947, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
Interventions
- DRUG KN046
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925947
The ClinicalTrials.gov registry entry for NCT04925947 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KN046 is the first listed.
NCT04925947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04925947 about?
NCT04925947 is a clinical study titled "A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors". This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
What is the current status of trial NCT04925947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-12-13. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04925947?
The interventions under investigation include: KN046 (DRUG).
Who is sponsoring clinical trial NCT04925947?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.